B7-H3-CAR T cells(St. Jude Children's Research Hospital)(B7-H3-CAR T cells(St. Jude Children's Research Hospital)) - 药物靶点：CD276_在研适应症：组蛋白H3中K27M点突变的弥漫性中线胶质瘤，室管膜瘤，胶质母细胞瘤_专利_临床

概要

基本信息

药物类型

自体CAR-T

别名-

靶点

CD276

作用机制

CD276调节剂(CD276抗原调节剂)、免疫细胞毒性、T淋巴细胞替代物

治疗领域

肿瘤神经系统疾病其他疾病

在研适应症

组蛋白H3中K27M点突变的弥漫性中线胶质瘤室管膜瘤胶质母细胞瘤+ [3]

非在研适应症-

原研机构

St. Jude Children's Research Hospital, Inc.

在研机构

St. Jude Children's Research Hospital, Inc.

非在研机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 B7-H3-CAR T cells(St. Jude Children's Research Hospital) 相关的临床试验

NCT05835687 / Recruiting临床1期IIT

Loc3CAR: Locoregional Delivery of B7-H3-specific Chimeric Antigen Receptor Autologous T Cells for Pediatric Patients With Primary CNS Tumors

Loc3CAR is a Phase I clinical trial evaluating the use of autologous B7-H3-CAR T cells for participants ≤ 21 years old with primary CNS neoplasms. B7-H3-CAR T cells will be locoregionally administered via a CNS reservoir catheter. Study participants will be divided into two cohorts: cohort A with B7-H3-positive relapsed/refractory non-brainstem primary CNS tumors, and cohort B with diffuse midline gliomas (DMG). Participants will receive four (4) B7-H3-CAR T cell infusions over a 4 week period. The purpose of this study is to find the maximum (highest) dose of B7-H3-CAR T cells that are safe to give patients with primary brain tumors.
Primary objectives
* To determine the safety, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) for the locoregional delivery of autologous B7-H3-CAR T cells in patients ≤ 21 years of age with recurrent/refractory B7-H3+ primary CNS tumors (Cohort A) or DMG (Cohort B).
Secondary objectives
* To assess the efficacy, defined as sustained objective response, a partial response (PR) or complete response (CR) observed anytime on active treatment with B7-H3-CAR T cells in patients with relapsed/refractory B7-H3+ primary CNS tumors (Cohort A) or DMG (Cohort B).
* To characterize and monitor neurologic toxicities in patients while on study (Cohort A and B).

开始日期2023-04-27

申办/合作机构

St. Jude Children's Research Hospital, Inc.

NCT04897321 / Recruiting临床1期IIT

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

3CAR is being done to investigate an immunotherapy for patients with solid tumors. It is a Phase I clinical trial evaluating the use of autologous T cells genetically engineered to express B7-H3-CARs for patients ≤ 21 years old, with relapsed/refractory B7-H3+ solid tumors. This study will evaluate the safety and maximum tolerated dose of B7-H3-CAR T cells.The purpose of this study is to find the maximum (highest) dose of B7-H3-CAR T cells that are safe to give to patients with B7-H3-positive solid tumors.
Primary objective
To determine the safety of one intravenous infusion of autologous, B7-H3-CAR T cells in patients (≤ 21 years) with recurrent/refractory B7-H3+ solid tumors after lymphodepleting chemotherapy
Secondary objective
To evaluate the antitumor activity of B7-H3-CAR T cells
Exploratory objectives
* To evaluate the tumor environment after treatment with B7-H3-CAR T cells
* To assess the immunophenotype, clonal structure and endogenous repertoire of B7-H3-CAR T cells and unmodified T cells
* To characterize the cytokine profile in the peripheral blood after treatment with B7-H3-CAR T cells

开始日期2022-07-06

申办/合作机构

St. Jude Children's Research Hospital, Inc.

100 项与 B7-H3-CAR T cells(St. Jude Children's Research Hospital) 相关的临床结果

登录后查看更多信息

100 项与 B7-H3-CAR T cells(St. Jude Children's Research Hospital) 相关的转化医学

登录后查看更多信息

100 项与 B7-H3-CAR T cells(St. Jude Children's Research Hospital) 相关的专利（医药）

登录后查看更多信息

39

项与 B7-H3-CAR T cells(St. Jude Children's Research Hospital) 相关的文献（医药）

2024-12-01·Molecular Immunology

Preclinical assessment of the efficacy of B7-H3 CAR-T in renal cell carcinoma

Article

作者: Li, Huizhong ; Wang, Fei ; Li, Hongxia ; Rao, Enyu ; Wang, Shiyuan ; Du, Hongwei ; Dotti, Gianpietro ; Zhao, Haifang ; Cao, Jiale ; Savoldo, Barbara

B7-H3 is a type I transmembrane protein that belongs to the B7 immune checkpoint protein family, is aberrantly expressed in cancer cells, but rarely expressed in normal tissues, making it an attractive target for cancer therapy. Here, we found B7-H3 is highly expressed in the renal cell carcinoma (RCC) tumor tissues and RCC cell lines, but is undetectable in normal renal tissues. Therefore, we engineered second-generation CAR-T cells targeting B7-H3, incorporating either CD28 or 4-1BB co-stimulatory domains. Both CAR-T cell variants demonstrated potent antitumor activity against RCC tumors in vitro and in metastatic and orthotopic RCC mouse models. Furthermore, the B7-H3 CAR-T cells exhibited remarkable proliferation and robust cytokine release when co-cultured with RCC cancer cells. These findings demonstrated that targeting B7-H3 by CAR-T cells potentially offering a new treatment option for RCC patients.

2024-10-01·Clinical Cancer Research

Redirecting B7-H3.CAR T Cells to Chemokines Expressed in Osteosarcoma Enhances Homing and Antitumor Activity in Preclinical Models

Article

作者: Nguyen, Phuong ; Fleming, Andrew ; Ross, Aaron B. ; Chockley, Peter J. ; Beckett, Alexandra ; Talbot, Lindsay J. ; Wang, Jian ; Gottschalk, Stephen ; Shepphard, Heather ; Chabot, Ashley ; DeRenzo, Christopher

AbstractPurpose:Clinical efficacy of chimeric antigen receptor (CAR) T cells against pediatric osteosarcoma (OS) has been limited. One strategy to improve efficacy may be to drive chemokine-mediated homing of CAR T cells to tumors. We sought to determine the primary chemokines secreted by OS and evaluate the efficacy of B7-H3.CAR T cells expressing the cognate receptors.Experimental Design:We developed a pipeline to identify chemokines secreted by OS by correlating RNA-seq data with chemokine protein detected in media from fresh surgical specimens. We identified CXCR2 and CXCR6 as promising receptors for enhancing CAR T-cell homing against OS. We evaluated the homing kinetics and efficiency of CXCR2- and CXCR6.T cells and homing, cytokine production, and antitumor activity of CXCR2- and CXCR6.B7-H3.CAR T cells in vitro and in vivo.Results:T cells transgenically expressing CXCR2 or CXCR6 exhibited ligand-specific enhanced migration over T cells modified with nonfunctional control receptors. Differential homing kinetics were observed, with CXCR2.T-cell homing quickly and plateauing early, whereas CXCR6.T cells took longer to home but achieved a similar plateau. When expressed in B7-H3.CAR T cells, CXCR2- and CXCR6 modification conferred enhanced homing toward OS in vitro and in vivo. CXCR2- and CXCR6-B7-H3.CAR-treated mice experienced prolonged survival in a metastatic model compared with B7-H3.CAR T-cell-treated mice.Conclusions:Our patient-based pipeline identified targets for chemokine receptor modification of CAR T cells targeting OS. CXCR2 and CXCR6 expression enhanced the homing and anti-OS activity of B7-H3.CAR T cells. These findings support clinical evaluation of CXCR-modified CAR T cells to improve adoptive cell therapy for patients with OS.

2024-09-10·Journal of clinical oncology : official journal of the American Society of Clinical Oncology

STRIvE-02: A First-in-Human Phase I Study of Systemically Administered B7-H3 Chimeric Antigen Receptor T Cells for Patients With Relapsed/Refractory Solid Tumors.

Article

作者: Park, Julie R ; Pinto, Navin ; Brown, Christopher ; Pattabhi, Sowmya ; Huang, Wenjun ; Cheeney, Safia H E ; Gustafson, Joshua A ; Orentas, Rimas J ; Wilson, Ashley L ; Gustafson, Heather H ; Burleigh, Katelyn ; Ullom, Heidi B ; Taylor, Mallory R ; Rawlings-Rhea, Stephanie D ; Vitanza, Nicholas A ; Albert, Catherine M ; Wendler, Jason ; Jensen, Michael C ; Seidel, Kristy ; Gardner, Rebecca A

PURPOSEB7-H3 is an immunoregulatory protein overexpressed by many pediatric solid tumors with limited expression on critical organs, making it an attractive immunotherapy target. We present a first-in-human phase I clinical trial systemically administered B7-H3 chimeric antigen receptor (CAR) T cells for young patients with relapsed or refractory solid tumors.PATIENTS AND METHODSPatients were enrolled onto a phase I trial to examine the safety of B7-H3-specific CARs at various dose levels (DLs) using a standard 3 + 3 dose escalation design.RESULTSSixteen patients (range, 11-24 years; median, 18.5 years) were enrolled, and nine were treated at DL1 (0.5 × 10⁶ CAR T cells/kg; n = 3) or DL2 (1 × 10⁶ CAR T cells/kg; n = 6). There were no first infusion dose-limiting toxicities. Maximum first-infusion circulating CAR T cells detected in the peripheral blood were 4.98 cells/μL (range, 0-4.98 cells/μL) with detection of CAR T cells colocalizing with tumor cells at the site of metastatic disease in one patient. Patients were eligible for subsequent infusions. An objective partial response by PERCIST criteria was observed 28 days after a second CAR T cell infusion in a patient who did not have an objective response after the first infusion. The second infusion demonstrated marked enhancement of CAR T cell expansion to 1,590 cells/μL and was accompanied by cytokine release syndrome and dose-limiting transaminitis. Detailed peripheral blood cytokine profiling revealed elevated IL-21 levels preinfusion 2 compared with infusion 1.CONCLUSIONB7-H3 CAR T cells are tolerable and demonstrate limited antitumor activity without acute on-target, off-tumor toxicity. High levels of CAR T cell expansion may be necessary to achieve objective responses, but undefined host and tumor microenvironment factors appear to be critical (ClinicalTrials.gov identifier: NCT04483778).

100 项与 B7-H3-CAR T cells(St. Jude Children's Research Hospital) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
组蛋白H3中K27M点突变的弥漫性中线胶质瘤	临床1期	美国	St. Jude Children's Research Hospital, Inc.	2023-04-27
室管膜瘤	临床1期	美国	St. Jude Children's Research Hospital, Inc.	2023-04-27
胶质母细胞瘤	临床1期	美国	St. Jude Children's Research Hospital, Inc.	2023-04-27
高级别胶质瘤	临床1期	美国	St. Jude Children's Research Hospital, Inc.	2023-04-27
髓母细胞瘤	临床1期	美国	St. Jude Children's Research Hospital, Inc.	2023-04-27
非典型畸胎瘤	临床1期	美国	St. Jude Children's Research Hospital, Inc.	2023-04-27